Kornitzer Capital Management Inc. KS purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent filing with the SEC. The firm purchased 36,770 shares of the medical research company’s stock, valued at approximately $4,348,000.

Other large investors also recently made changes to their positions in the company. YorkBridge Wealth Partners LLC bought a new stake in shares of Edwards Lifesciences Corporation during the first quarter valued at approximately $110,000. NEXT Financial Group Inc raised its stake in shares of Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares in the last quarter. Cornerstone Advisors Inc. raised its stake in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares in the last quarter. Alexandria Capital LLC raised its stake in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its stake in shares of Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares in the last quarter. Hedge funds and other institutional investors own 83.80% of the company’s stock.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 116.19 on Friday. The company has a 50 day moving average of $117.23 and a 200 day moving average of $104.41. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The firm has a market cap of $24.53 billion, a PE ratio of 35.24 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.76 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.64 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/06/kornitzer-capital-management-inc-ks-takes-position-in-edwards-lifesciences-corporation-ew.html.

Several equities research analysts recently commented on the stock. Jefferies Group LLC lifted their price target on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Bank of America Corporation lifted their price target on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Canaccord Genuity reissued a “buy” rating and set a $155.00 price objective (up from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Stifel Nicolaus reissued a “buy” rating and set a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Finally, Cowen and Company reissued an “outperform” rating and set a $135.00 price objective (up from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $121.13.

In related news, VP Donald E. Bobo, Jr. sold 19,100 shares of the stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $110.34, for a total value of $2,107,494.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Insiders sold a total of 144,612 shares of company stock valued at $16,567,653 in the last quarter. 2.13% of the stock is currently owned by insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.